Purpose: To determine the efficacy, safety, predictability, and stability of laser in situ keratomileusis (LASIK) in the treatment of presbyopia.
Methods: The databases of CNKI, VIP, Wan-Fang, CBM, Chinese Clinical Registry, PubMed, The Cochrane Library, Web of Science, Embase, and ClinicalTrials.gov were searched until March 2023. The authors chose the studies of LASIK in the treatment of presbyopia. Outcomes were efficacy, safety, predictability, and stability. The review was registered in the international platform of registered systematic review and meta-analysis protocols (INPLASY202350005).
Results: A total of 28 non-randomized controlled trials (15,861 eyes) were included. The results showed that after LASIK, (1) the distance efficacy decreased (mean difference [MD]: 0.02, 95% CI: 0.0 to 0.03, P < .05) and the near efficacy increased (MD: -0.01, 95% CI: -0.19 to-0.02, P < .05); (2) the distance safety decreased (MD: 0.07, 95% CI: 0.04 to 0.10, P < .0001) and near safety increased (MD: -0.19, 95% CI: -0.39 to 0.02, P > .05); (3) the predictability within ±1.00 and ±0.50 D was 94% (relative risk [RR]: 0.94, 95% CI: 0.90 to 0.98, P < .001) and 80% (RR: 0.80, 95% CI: 0.74 to 0.86, P < .001), respectively; and (4) 6 months postoperatively, the percentage of spherical equivalent changing within ±0.50 D was 95% (RR: 0.95, 95% CI: 0.89 to 0.99, P < .001).
Conclusions: The near efficacy, predictability, and stability of LASIK for presbyopia correction were satisfactory; however, the distance efficacy and distance safety decreased. [J Refract Surg. 2023;39(9):627-638.].